Aslan Pharmaceuticals Limited (ASLN) - News Archive

On July 9, 2024, ASLAN Pharmaceuticals received notification from the staff of the Listing Qualifications Department at Nasdaq regarding its non-compliance with the $1.00 bid price and $2.5 million stockholders equity r...

ASLAN Pharmaceuticals Ltd ADR (NASDAQ: ASLN) has been gaining significant attention in the biotechnology and medical research industry. Recent developments, including a positive rating upgrade and fluctuations in stock...

ASLAN Pharmaceuticals, a leading biopharmaceutical company, recently announced plans to change the ratio of its American Depositary Shares (ADSs) to ordinary shares. This change, from one ADS representing twenty-five or...

ASLAN Pharmaceuticals Expands Collaboration with Zenyaku to Investigate Eblasakimab s Unique Biology in Comparison to Other BiologicsMay 2, 2024 ASLAN Pharmaceuticals (Nasdaq: ASLN) has recently announced an extension o...

Groundbreaking Eblasakimab Shows Remarkable Efficacy in Dupilumab-Experienced Atopic Dermatitis PatientsASLAN Pharmaceuticals, a pioneering biopharmaceutical company, recently revealed promising interim results from a p...

SAN MATEO, Calif. and SINGAPORE, March 12, 2024 ASLAN Pharmaceuticals Ltd., a prominent immunology focused biopharmaceutical company, recently revealed plans for a landmark $5 million registered direct offering. The com...

ASLAN Pharmaceuticals, a leading biopharmaceutical company focused on immunology, has recently provided an important update regarding its ongoing TREK-DX trial. The study aims to evaluate the efficacy and safety of ebla...

ASLAN Pharmaceuticals Announces Positive Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific AdvisorsSan Mateo, Calif. and Singapore March 06, 2024 ASLAN Pharmaceuticals Ltd....